Sector
PharmaceuticalsOpen
₹535Prev. Close
₹529.95Turnover(Lac.)
₹2,812.77Day's High
₹543Day's Low
₹51052 Week's High
₹1,175.952 Week's Low
₹405Book Value
₹80.01Face Value
₹2Mkt Cap (₹ Cr.)
8,351.33P/E
108.93EPS
4.87Divi. Yield
0The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 28.61 | 28.61 | 14.31 | 1.3 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 115.27 | 282.89 | 171.23 | 565.75 |
Net Worth | 143.88 | 311.5 | 185.54 | 567.05 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|
Gross Sales | 4,178.18 | 3,654.82 | 3,671.89 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 4,178.18 | 3,654.82 | 3,671.89 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 34.03 | 46.11 | 22.83 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,787.4 | 137.43 | 4,32,960 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,012.5 | 79.59 | 1,65,003.32 | 594 | 0.48 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,525.9 | 26.92 | 1,25,285.64 | 1,438.15 | 0.84 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,238.9 | 61.67 | 1,12,502.67 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,557.5 | 55.53 | 1,07,385.94 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
SANDEEP JAIN
Managing Director
SANJEEV JAIN
Independent Director
Matangi Gowrishankar
Company Sec. & Compli. Officer
Dharamvir Malik
Independent Director
Kewal Kundanlal Handa
Independent Director
NAND LAL KALRA
Whole-time Director
Sanjay Sinha
Non Executive Director
SUNIL KUMAR THAKUR
Independent Director
SATWINDER SINGH
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Akums Drugs & Pharmaceuticals Ltd
Summary
Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services. Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation. Their specialization extends to development and sale of APIs across diverse chemical processes and therapeutic areas such as anti-infective, respiratory and diabetes. In 2004, the Company established first plant for oral dosage commissioned at 19, 20, 21, Sector 6A, Haridwar, Uttarakhand. In 2007, it established dedicated manufacturing site for oral liquid dosage and sterile products both at Haridwar, Uttarakhand. It incorporated Maxcure Nutravedics Limited to venture into nutraceuticals in 2009. In 2010, it dedicated a facility for hormones ; de
Read More
The Akums Drugs & Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹530.6 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Akums Drugs & Pharmaceuticals Ltd is ₹8351.33 Cr. as of 25 Apr ‘25
The PE and PB ratios of Akums Drugs & Pharmaceuticals Ltd is 108.93 and 3.73 as of 25 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Akums Drugs & Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Akums Drugs & Pharmaceuticals Ltd is ₹405 and ₹1175.9 as of 25 Apr ‘25
Akums Drugs & Pharmaceuticals Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at -33.44%, 6 Month at -39.46%, 3 Month at -6.67% and 1 Month at 7.92%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.